HCPLive

Top Medical News Today

Exploring Treatment Failure Among Hepatitis C Patients
Although direct acting antivirals (DAAs) have revolutionized the treatment of hepatitis C virus (HCV), a small fraction of patients still experience treatment failure.
Erelzi, a biosimilar of Enbrel (etanercept), has received FDA approval. Biosimilars are defined by the organization as being “highly similar to an FDA-approved biological product” while demonstrating “clinically meaningful differences in terms of safety and effectiveness.”
It has been more than 30 years since the popular television show M*A*S*H went off the air but there is still much that can be learned from the show, particularly when it comes to psychiatry in the military.
As conditions like PTSD have been brought to the forefront work has been done to help not only current service members but also veterans who may be dealing with that and other conditions during and after service.
In a team approach to medicine there can be a variety of specialties included in helping improve a patient's overall well being. In some places art therapy is being included in this approach.
Thousands of cardiologists and other attendees at the ESC Congress 2016 got to meet Pope Francis, who told them he marveled at the science and human mystery of the heart.
In many cases, the latest treatments for hepatitis C virus (HCV) infection are at least 90% effective at curing the infection; however, there still remains a subset of patients who don’t respond to the new medications.
At The European Society of Cardiology Congress 2016 (ESC), Ibrahim Danad, MD, VU University Medical Center, Amsterdam, Netherlands, explained the results from his team's PACIFIC trial, which assessed two non-invasive coronary artery imaging tools: positon emission tomography (PET) and single photon emission computed tomography (SPECT).

Most Popular

@MDMagazine

$vacMongoViewPlus$ $vAR$